Leading the transition to precision medicine.

GeneType is leading the field of personalised, preventive medicine, also known as precision medicine. We are focused on developing the next generation of integrated predictive genetic testing and assessment tools – empowering medical practitioners and their patients to proactively manage health.

Multitest V3 2024


GeneType Multi Test

A combination of geneType tests for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type 2 diabetes in a single test.

Know your risk of a serious disease to tailor a personalised prevention plan with your medical practitioner.

Our pipeline

We have a strong pipeline of tests covering a wide range of serious conditions that are currently in various stages development, accreditation and approval.

Phase 2 launch of the Genetype Multi-Risk Test

Introducing Melanoma, Pancreatic Cancer and Atrial Fibrillation

Expanding our capability, introducing NIPT and Carrier testing
Development of Epigenetics Division
  • Phase 1 Methylation tests
  • Phase 2 Mutation tests

Accredited For Compliance With NPAAC Standards And ISO 15189

CLIA Number 99D2023356

Keep up-to-date with our latest advances

Sign up to our newsletter to stay informed about our latest advances and how these could support you.